Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average – What’s Next?

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Fortress Biotech Investigated by the Portnoy Law Firm

INVESTOR ALERT: Investigation of Fortress Biotech, Inc. (FBIO) Announced by Holzer & Holzer, LLC

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Journey Medical Corporation to Present at the Emerging Growth Conference

Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors